Macro Group Pharmaceutical S.a.e. · EGX:MCRO
Macro Group Pharmaceutical S.a.e — H1 2025 Earnings Presentation
18 slides from Macro Group Pharmaceutical S.a.e's earnings presentation, April 2026
Slide 1: Investor Relations Presentation 1H 2025
Investor Relations Presentation 1H 2025
Slide 2: Agenda
Agenda 1 Executive Summary 2 1H25 Financial & Operational Performance 3 Annual Achievements and Plan 4 Appendix
Slide 3: Executive Summary
Executive Summary
Slide 4: Executive Summary: 1H 2025 Financial and Operational Highlights
Executive Summary 1H 2025 Financial Highlights EGP 412 mn EGP 280 mn EGP 93.3 mn Revenues(1) Gross Profit Adjusted EBITDA (2) 165.0% YoY 189.0% YoY / 68.1% margin Vs. EGP -18.7 mn in 1H24 / 22.7% margin EGP 68.9 mn EGP 73.9 mn EGP 38.1 mn Net Profit Normalized Net profit(1) Operating Cashflow Vs
Slide 5: 1H25 Financial & Operational Performance
1H25 | Financial & Operational Performance
Slide 6: 1H25 Income Statement Highlights
1H25 |Income Statement Highlights 1H25 Highlights Revenues (1) Volume Sold Gross Profit (EGP mn) (mn units) (EGP mn/% margin) • Macro’s net revenues was up by a significant 165% YoY reaching EGP 412 million in 1H25, the growth was primarily due to the total 62.4% 68.1% volumes sold more than doublin
Slide 7: 2Q25 Income Statement Highlights
2Q25 |Income Statement Highlights 2Q25 Highlights Revenues(1) Volume Sold Gross Profit (EGP mn) (mn units) (EGP mn/% margin) • Macro’s revenues booked EGP 228 million in 2Q25, Up by 138% against the 95.7 million booked in 2Q24, on the back of higher volumes sold during the period. On a quarter-on-qu
Slide 8: 2Q25 Income Statement QoQ Highlights
2Q25 |Income Statement QoQ Highlights Revenues(1) Volume Sold Gross Profit (EGP mn) (mn units) (EGP mn/% margin) 66% 70% 228.0 4.3 159.2 23% 13% 31% 121.1 3.8 184.0 1Q25 2Q25 1Q25 2Q25 1Q25 2Q25 EBITDA(2) Net Income Normalized Net Income(2) (EGP mn/% margin) (EGP mn/% margin) (EGP mn/% margin) 66% 7
Slide 9: 1H25 Actual Vs Budget Vs Last Year
1H25 | Actual Vs Budget Vs Last Year 1H-2025 1H-2025 1H-2024 Consolidated Income Statement | EGP A Vs B YOY Actual Budget Actual Sales 411,541,394 379,368,600 8% 155,252,205 165% Cost of sales (131,244,142) (169,731,947) -23% (58,402,003) 125% Gross profit 280,297,252 209,636,653 34% 96,850,202 189%
Slide 10: 1H25 Quarterly PL Evolution 1Q24 : 2Q25
1H25 | Quarterly PL Evolution 1Q24 : 2Q25 Consolidated statement of profit or loss 1Q24 2Q24 2Q24 4Q24 1Q25 2Q25 Sales 59,536,121 95,716,084 163,955,577 200,761,775 184,387,191 227,154,203 Cost of sales (23,054,632) (35,347,371) (67,456,359) (70,991,687) (63,274,601) (67,969,541) Gross profit 36,481
Slide 11: Annual Achievements and Plan
Annual Achievements and Plan
Slide 12: Driving Growth Across Functions: Sales and Marketing
1H25: Driving Growth Across Functions Revenues | EGP mn Sales and Marketing June 24 to June 25 We secured strong demand dynamics, reflected in Sales in / Out a healthy in/out ratio that surpassed sales targets. 100 89 85 85 79 83 79 79 77 Additionally summer campaigns were launched to 76 Sales growt
Slide 13: 1H25 Export Highlights
1H25 | Export Highlights Total Export Revenues | EGP mn Export breakdown by country | H125 177% Y-o-Y 15 Exports were up to reach EGP 17.5 million up from 14 1% 3% 2% 4% EGP 6.3 million “rising from USD 131.5K to USD 12 347.7K a 164% increase year-over-year” 10% Exports now contribute 4% of total
Slide 14: Driving Growth Across Functions – Departments Milestones
1H25: Driving Growth Across Functions – Departments Milestones The Plant has successfully renewed the industrial registration for five years following a thorough inspection and approval by both the EDA and IDA, All previously raised observations from both authorities were fully addressed and resolve
Slide 15: Driving Growth Across Functions – Marketing Activities
1H25: Driving Growth Across Functions – Marketing Activities Macroverse a Mega Macro event Attendance Lucente On ground and Digital campaign with 10 Macro Talks podcast set up (interview) to 250 Dermatologists to generate high impact carefully selected influencers this mix includes discuss selected
Slide 16: Appendix
OY QO Appendix
Slide 17: 1H25 Consolidated Income Statement
1H25 | Consolidated Income Statement 1H-2025 1H-2024 Consolidated Income Statement | EGP YOY Actual Actual Sales 411,541,394 155,252,205 165% Cost of sales (131,244,142) (58,402,003) 125% Gross profit 280,297,252 96,850,202 189% Gross profit margin 68% 62% 5.7 pps Selling and marketing expenses (130
Slide 18: 1H25 Consolidated Balance Sheet
1H25 | Consolidated Balance Sheet Consolidated Balance Sheet | EGP Jun-25 Dec-24 % CHG Y-o-Y Inventories 104,815,412 103,064,012 1.70% Trade and notes receivables 317,011,022 298,125,499 6.33% Prepayments & other debit balances 61,674,780 50,746,961 21.53% Cash & cash equivalents 109,478,540 62,337,
Macro Group Pharmaceutical S.a.e. — H1 2025 Earnings Presentation on 6ix